Explore
Validate
LearnNB120-22711
antibody from Novus Biologicals
Targeting: MUC1
ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM
ELISA
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [15]
- Comments [0]
- Validations
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NB120-22711 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NB120-22711, RRID:AB_789083
- Product name
- Mouse Monoclonal MUC1 Antibody
- Antibody type
- Monoclonal
- Description
- Protein G purified. Reacts very little with normal tissue. Found to react with breast, colon and ovarian carcinomas and adinocarcinoma. SM3 recognises the under-glycosylated form of MUC1 and is therefore tumour specific.
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 0.1 ml
- Concentration
- 1.0 mg/ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1.
Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma In situ of the breast.
Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma In situ of the breast.
Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation.
Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation.
Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation.
MUC1 glycoforms in breast cancer--cell line T47D as a model for carcinoma-associated alterations of 0-glycosylation.
MUC1 glycoforms in breast cancer--cell line T47D as a model for carcinoma-associated alterations of 0-glycosylation.
Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells.
Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells.
Association of sialyl-Lewis(a) and sialyl-Lewis(x) with MUC-1 apomucin ina pancreatic cancer cell line.
Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients.
Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice.
Sørensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, Sankaranarayanan V, Schwientek T, Graham R, Taylor-Papadimitriou J, Hollingsworth MA, Burchell J, Clausen H
Glycobiology 2006 Feb;16(2):96-107
Glycobiology 2006 Feb;16(2):96-107
The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1.
Dalziel M, Whitehouse C, McFarlane I, Brockhausen I, Gschmeissner S, Schwientek T, Clausen H, Burchell JM, Taylor-Papadimitriou J
The Journal of biological chemistry 2001 Apr 6;276(14):11007-15
The Journal of biological chemistry 2001 Apr 6;276(14):11007-15
Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma In situ of the breast.
Mommers EC, Leonhart AM, von Mensdorff-Pouilly S, Schol DJ, Hilgers J, Meijer CJ, Baak JP, van Diest PJ
International journal of cancer 1999 Oct 22;84(5):466-9
International journal of cancer 1999 Oct 22;84(5):466-9
Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma In situ of the breast.
Mommers EC, Leonhart AM, von Mensdorff-Pouilly S, Schol DJ, Hilgers J, Meijer CJ, Baak JP, van Diest PJ
International journal of cancer 1999 Oct 22;84(5):466-9
International journal of cancer 1999 Oct 22;84(5):466-9
Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P, Kandilogiannaki M, Petrarca C, von Mensdorff-Pouilly S, Hilgers JH, Krambovitis E, Arends JW, Hoogenboom HR
Cancer research 1998 Oct 1;58(19):4324-32
Cancer research 1998 Oct 1;58(19):4324-32
Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation.
Karsten U, Diotel C, Klich G, Paulsen H, Goletz S, Müller S, Hanisch FG
Cancer research 1998 Jun 15;58(12):2541-9
Cancer research 1998 Jun 15;58(12):2541-9
Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation.
Böhm CM, Mulder MC, Zennadi R, Notter M, Schmitt-Gräff A, Finn OJ, Taylor-Papadimitriou J, Stein H, Clausen H, Riecken EO, Hanski C
Scandinavian journal of immunology 1997 Jul;46(1):27-34
Scandinavian journal of immunology 1997 Jul;46(1):27-34
Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation.
Böhm CM, Mulder MC, Zennadi R, Notter M, Schmitt-Gräff A, Finn OJ, Taylor-Papadimitriou J, Stein H, Clausen H, Riecken EO, Hanski C
Scandinavian journal of immunology 1997 Jul;46(1):27-34
Scandinavian journal of immunology 1997 Jul;46(1):27-34
MUC1 glycoforms in breast cancer--cell line T47D as a model for carcinoma-associated alterations of 0-glycosylation.
Hanisch FG, Stadie TR, Deutzmann F, Peter-Katalinic J
European journal of biochemistry 1996 Feb 15;236(1):318-27
European journal of biochemistry 1996 Feb 15;236(1):318-27
MUC1 glycoforms in breast cancer--cell line T47D as a model for carcinoma-associated alterations of 0-glycosylation.
Hanisch FG, Stadie TR, Deutzmann F, Peter-Katalinic J
European journal of biochemistry 1996 Feb 15;236(1):318-27
European journal of biochemistry 1996 Feb 15;236(1):318-27
Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells.
Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylor-Papadimitriou J
European journal of biochemistry 1995 Oct 15;233(2):607-17
European journal of biochemistry 1995 Oct 15;233(2):607-17
Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells.
Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylor-Papadimitriou J
European journal of biochemistry 1995 Oct 15;233(2):607-17
European journal of biochemistry 1995 Oct 15;233(2):607-17
Association of sialyl-Lewis(a) and sialyl-Lewis(x) with MUC-1 apomucin ina pancreatic cancer cell line.
Ho JJ, Siddiki B, Kim YS
Cancer research 1995 Aug 15;55(16):3659-63
Cancer research 1995 Aug 15;55(16):3659-63
Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients.
Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ
Cancer research 1994 Jun 1;54(11):2856-60
Cancer research 1994 Jun 1;54(11):2856-60
Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice.
Peat N, Gendler SJ, Lalani N, Duhig T, Taylor-Papadimitriou J
Cancer research 1992 Apr 1;52(7):1954-60
Cancer research 1992 Apr 1;52(7):1954-60
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: MUC-1 Antibody (SM3) [NB120-22711] - IHC analysis of formalin fixed paraffin embedded tissue section of human breast cancer xenograft using MUC-1 antibody clone SM3 at 1:10 dilution. The xenograft section depicted a very specific and intense signal in the periphery of the cancer cells. The necrotic cells also developed a strong diffused immune-positivity while the tumor stroma as well as the nuclei of cells were negative for immunostaining.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: MUC-1 Antibody (SM3) [NB120-22711] - IHC analysis of formalin fixed paraffin embedded tissue section of human breast cancer xenograft using MUC-1 antibody clone SM3 at 1:10 dilution. The xenograft section depicted a very specific and intense signal in the periphery of the cancer cells. The necrotic cells also developed a strong immune-positivity while the tumor stroma as well as the nuclei of cells were negative for immunostaining.
